The hypothesis that differences in diet can change breast cancer and heart disease incidence in postmenopausal women is at least, in part, proposed based on results generated from studies on phytoestrogens. Phytoestrogens are plant chemicals that bind to the estrogen receptor and induce many components of estrogen action (2) (3) (4) (5) (6) (7) (8) (9) (10) . The best known phytoestrogens are diphenolic chemicals that belong to the classes of flavonoids, isoflavonoids, and lignans (2) (3) (4) (5) (6) (7) (8) (9) (10) . These compounds are thought to play a beneficial role in preventing breast cancer. They may function as antiestrogens or weak estrogens by competing with estrogens for binding to the estrogen receptor (ER). However, we feel that it is also possible that some of these compounds may act in an indirect fashion by inhibiting aromatase activity, resulting in a decrease in the level of estrogen in women. This aspect may have been overlooked.
In estrogen-dependent breast tumors, estrogens induce the expression of peptide growth factors that are responsible for the proliferative responses of cancer cells (11, 12) . Aromatase, a cytochrome P450, is the enzyme synthesizing estrogens by catalyzing three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogenic steroids (Fig. 1) . Because aromatase is the enzyme responsible for the synthesis of estrogens and because estrogens have a major effect on the development of breast cancer, an abnormal expression of aromatase in breast cancer cells or surrounding adipose stromal cells may have a significant influence in breast tumor maintenance and growth in breast cancer patients. Cell culture and nude mouse studies using aromatase-transfected and T-47D cells (13) (14) (15) have demonstrated that tumor aromatase can play a role in breast cancer maintenance and progression. It has also been suggested that in situ produced estrogen plays a more important role than circulating estradiol in breast tumor promotion (16, 17) . Estrogen synthesized by the tumor aromatase was shown to stimulate breast tumor growth in both an autocrine and a paracrine manner (15) . Aromatase-inhibitor therapy is a second-line treatment for those who fail anti estrogen therapy. Twenty to 30% of the patients who fail antiestrogen treatment respond to aromatase-inhibitor treatment. Phytoestrogens have been reported to be inhibitors of aromatase (18) (19) (20) (21) (22) (28) (29) (30) . Recently, the binding characteristics of seven aromatase inhibitors were determined using the above approaches (30) . In this paper, we report the inhibition profiles of eight phytoestrogens on the wild-type aromatase and six mutants. By analyzing these results together with results generated previously with well-characterized aromatase inhibitors (28) (29) (30) Molecular modeling. The generation of a three-dimensional model of human aromatase has been described previously (31) . The modeling of the binding of phytoestrogens in the active site was performed using the program BIOGRAF, a molecular modeling program marketed by Molecular Simulations, Inc. (Waltham, MA). The phytoestrogens were built using fragment libraries supplied with the program. Partial charges were assigned using the QEquilibrate algorithm. The initial structures, most of which were semirigid, were flrst energy minimized to a root-meansquare (RMS) force of less than 0.001. The resulting structures were subjected to 1 psec of molecular dynamics at 300 K, followed by conjugate gradient minimization to an RMS force of less than 0.001.
The minimized phytoestrogen molecules were then individually placed within the active site of the aromatase model such that overlap with the bound substrate was optimal. Each inhibitor was again energy minimized, but this time in the context of the active site (indudes all residues within 10 A of the inhibitor). This optimized the position of each inhibitor within the pocket, assuming that the pocket was rigid. Finally, we repeated the minimizations, assuming that residues within the active site can move to better accommodate the inhibitors (induced fit theory of molecular interaction) to see if the results better explain the inhibition binding data generated in our laboratory.
Stable expression and site-directed mutagenesis experiments. Aromatase mutant cDNAs were generated using a PCR-based mutagenesis method, which was described in a previous publication (30 (23, 24, 26, 30) . A detailed discussion of the catalytic properties of these six mutants has been published (30) .
Other experiments. The aromatase activity was determined by a 3H20 release assay, as described by Zhou et al. (33) . This 3H20 release assay for human aromatase expressed in CHO cells was previously validated by the product isolation assay (33) . For the aromatase inhibition study, phytoestrogens were dissolved in dimethylsulfoxide and added during the assays with 100 nM [11-3H] androstenedione. In addition, the inhibition profile studies were performed using an in-cell method; the results produced by the in-cell method have been shown to be comparable to those determined using microsomal preparations of aromatase and its mutants (30 (30) .
In the I helix, there is a conserved threonine (Thr) residue in all the known cytochrome P450 structures except P450eryF (38) , and Thr-310 in aromatase is the conserved residue. Thr-310 appears to be involved in stabilizing the distortion in the I helix by providing a hydrogen bond to the carbonyl group of alanine (Ala)-306; in addition, it may act as a proton donor during the redox reactions (30) . Furthermore, the increased sensitivity of the mutant T310S to several nonsteroidal aromatase inhibitors suggests that, in the normal enzyme, the methyl group of Thr-310 may be involved in steric clashes with such inhibitors, somewhat reducing their binding affinity (30) . The residue adjacent to the conserved threonine residue is an aspartic acid which is also highly conserved in cytochromes P450. Studies have suggested that aspartic acid (Asp)-309 is an important residue in the active site of aromatase (24, 34 ). An Asp-309 to Ala mutation could cause a partial collapse in the active site cavity that reduces the ability ofall the studied inhibitors, except aminoglutethimide (AG), to bind to aromatase (30) . AG is smaller than the androgen substrate, and the enhanced inhibition of D309A may result from a tighter binding of AG in an active site cavity of reduced volume. In addition, a characteristic of cytochrome P450 structures is the distortion in the central region of the I helix with the formation of a deft in the region of the heme iron. In the cytochrome P450cam-based model of aromatase, proline (Pro)-308 forms part of this cleft. Interestingly, the aromatase mutant Volume 106, Number 2, February 1998 * Environmental Health Perspectives P308F was found to be more sensitive to treatment by two steroidal inhibitors [4-hydroxyandrostenedione (4-OHA) and 7a-(4 '-amino)phenylthio-1 ,4-androstadiene-3,17-dione (7aAPTADD)] than the wild type enzyme (30) .
Isoleucine (Ile)-474 in the carboxy terminus of aromatase corresponds to Ile-395, an active site residue in cytochrome P450cam, and is thought to be situated around the lower edge of the B ring of the androgen substrate in aromatase (30) . Ile-395 is in a region (residues 380-402) conserved among aromatase of all species analyzed so far. The Km value of androstenedione for I395F was found to be significantly larger than that of the wild-type aromatase (30) , suggesting that the mutation reduces the binding affinity of the substrate.
To study how flavone phytoestrogens interact with aromatase, we investigated the interaction of eight phytoestrogens, induding both flavones and isoflavones, with the wildtype aromatase and six well-characterized mutants, i.e., 1133Y, P308F, D309A, T31OS, I395F, and 1474Y. Previous studies from our laboratory have found that these mutations significantly affect the binding of the substrates and inhibitors of the enzyme (23, 24, 26, 30) .
Inhibition of aromatase by phytoestrogens. Figure 2 shows a computer-generated model of the active site region of aromatase along with the substrate androstenedione. The positions of Ile-133, Pro-308, Asp-309, Thr-310, Ile-395, and Ile-474 are highlighted.
The inhibition study involved four flavones [chrysin (5,7- Table 1 . Among the four flavones tested, chrysin is the best inhibitor. We modeled the binding of chrysin to the active site of aromatase based on the model for an aromatase inhibitor, vorozole, because of the resemblance in inhibition profiles with the an orientation in which the A and C rings of flavone mimic rings C and D of a steroid (see Fig. 2B ). By doing so, the p-phenyl substituent (i.e., ring B) of chrysin is oriented in a similar position to that of the substrate's ring A and is directed towards Asp 309. The p-phenyl substituent tilts approximately 300 in reference to rings A and C of the flavone (see Fig. 2B ). The C4-keto group of chrysin points towards the heme prosthetic group (Fig. 2C) . Our computer modeling analysis places the C4-keto group of flavones in an area for the angular C19 of the androgen steroid. Ibrahim and Abul-Hajj (19) reported that a reduction of the C4-keto group to a hydroxyl group greatly decreased the inhibitory potency. As indicated above, the low-spin nature of a-naphthoflavoneenzyme complex led Kellis and Vickery (18) to suggest the presence of an additional axial ligand to the heme-iron, possibly the with the mutant I133Y ( The results for galangin indicate that the presence of a hydroxyl group at position 3 of the flavone significantly reduces its ability to bind to aromatase. Computer modeling has revealed that the 3-hydroxyl group is pointing to the I-helix and affects the orientation of the phenyl substituent at the C-2 position and may also interfere with the interaction of the 4-keto group with the heme. Two types of inhibition profiles were observed for this compound; three mutants with changes located on the distal helix (P308F, D309A, and T310S) exhibited regular dose-dependent profiles, while the other three mutants as well as the wild-type enzymes exhibited unusual biphasic profiles (Fig. 5) . The 3-hydroxyl group of galangin and Thr-310 of the enzyme are thought to be on the same side of the beta-face of the flavone's ring-C. If a larger accessible volume of the binding cavity is obtained by removing the methyl group of threonine at position 310, galangin could bind better in the resulting active site. Our inhibition studies have shown that T31OS is more sensitive to galangin than the wild-type aromatase at concentrations less than 150 pM (Fig. 5) . Contrary to chrysin and other flavones, galangin binds relatively better to the mutant D309A than to the wild-type enzyme, suggesting that galangin fits better in the active site with a Asp-309 to Ala mutation. The nature of the biphasic inhibition profiles is not known. There is a possibility that galangin interacts with other proteins in CHO cells. However, an interaction with other proteins cannot explain why biphasic inhibition profiles were found for some but not all mutant forms of the enzyme. At the present time, we cannot explain these results adequately. As predicted from the computer model, the increased potency of galangin for I474Y may be due to a favorable aromatic-aromatic interaction between the p-phenyl substituent and the mutated residue. Since both chrysin and galangin bear the same A ring, the relative potency of I1 33Y to wild-type aromatase exerted by these compounds has been found to be comparable in the two compounds.
a-Naphthoflavone, but not P-naphthoflavone, is a good inhibitor of aromatase. a-Naphthoflavone has an additional benzoring at the C-7 and C-8 positions of ring-A of flavone. When superimposed over the structure of chrysin, the C4-keto group of a-naphthoflavone points closer to the heme, implying a better fit in the active site of aromatase (see Fig. 2C ). A smaller KJ value of a-naphthoflavone for P308F than the wild-type aromatase suggests further that the binding orientation of a-naphthoflavone is slightly different from that of chrysin. As discussed above, Kellis and Vickery (18) observed that removal of the C4-keto group of 7,8-benzoflavone's pyranone C-ring to a furan ring totally diminished the inhibition ability, again indicating that the 4-keto group is essential for the inhibition of aromatase. P-Naphthoflavone has a structure very different from a-naphthoflavone and does not fit in the active site of the enzyme; this agrees with our inhibition experiment, which indicates that Pnaphthoflavone is a very poor inhibitor (results not shown).
Naringenin is slightly less potent than chrysin, but the inhibition profiles of naringenin were found to be similar to those of chrysin. These results indicate that a conversion of C2, C3 double bond to a single bond has only a small effect on its binding when compared to chrysin. In fact, the C2 atom in naringenin is a chiral center. Our computer modeling has revealed that only the S-configuration isomer can bind to the active site. Therefore, the observed Ki values might originate from a racemic mixture and the actual Ki values for the S-configuration isomer may be lower than those shown in Table 1 . However, the presence of a single bond between the C-2 and C-3 positions does slightly modify the conformation of ring C (as shown by the computer modeling), explaining why there was an increase in the K; value for I133Y by comparing it to that of chrysin. On the other hand, the presence of a 4'-hydroxyl group has only a small influence on the binding of the compound, as indicated by similar inhibitory profiles as chrysin for the mutants P308F, D309A, and T310S. Our computer modeling reveals that isoflavones may enter the active site pocket in a similar way as flavones in that ring B is positioned near the distal helix and the C4-keto group is pointing towards the heme (see Fig. 2D ). Computer modeling suggests that the pocket on the distal helix side may be more compact or rigid so that ring B of chrysin and the two isoflavones have to be held at about the same position. In contrast, the opposite side of the pocket is comparatively spacious (e.g., a-naphthoflavone binds stronger in the active site of aromatase) and therefore allows the benzopyranone rings of these compounds relatively free movement. Among these compounds, the C4-keto group of genistein is the farthest from the heme as seen in the model (Fig. 2D) (Fig.  2D) , explaining why the binding affinity of biochanin A was found to decrease in mutants P308F, D309A, and T31OS.
Flavone structure-activity studies from other laboratories (18) (19) (20) (21) and our present study have revealed the structural features for flavone and isoflavone phytoestrogens to inhibit aromatase. By evaluating the interaction of eight phytoestrogens with the wild-type aromatase and six mutants by computer modeling and inhibition profile analysis, we have obtained further information regarding how phytoestrogens bind to the active site of aromatase. Figure 6 summarizes our current knowledge as to how flavones bind to the active site of aromatase. These compounds bind to the active site in an orientation such that their A and C rings mimic rings D and C of the steroid, respectively. The C4-keto group points to the heme prosthetic group. The presence of a 5-hydroxy group reduces the binding affinity, probably by forming a hydrogen bond with the 4-keto group. 7-Hydroxy-and 8-hydroxy-containing flavones are reasonable inhibitors of aromatase. The C-6 position of flavones is situated in a very restricted area; therefore, any flavones that have a C-6 substituent cannot bind to the enzyme. Furthermore, a 3-hydroxy group significantly changes the orientation of ring B, resulting in a large decrease in the ability to inhibit aromatase. Isoflavones such as genistein and daidzein have the 4'-hydroxyphenyl group at position C-3, greatly reducing the ability to bind and inhibit aromatase. These isoflavones cannot bind to aromatase in an orientation in which rings A and C mimic rings A and B of the steroid because the 4'-hydroxy group will be situated in the area equivalent to the C-6 position in flavones. While it is possible that isoflavones without the 4'-hydroxy group may inhibit aromatase, such compounds are not yet available for our investigation. Ongoing research in this laboratory will evaluate the effect of the hydroxy substituents of ring B on the ability to inhibit aromatase.
The binding orientation of flavones and isoflavones in relation to steroids in the active site of aromatase is different to that proposed for their binding to the estrogen receptor (ER) (40, 41) . For ER, isoflavones were found to be better ligands than flavones, and rings A and C of isoflavones were thought to mimic rings A and B of estrogen. Furthermore, a 4'-hydroxy group is thought to be required to bind ER effectively (see Fig. 6 ). By using a yeast estrogen system (YES) in which yeast cells were cotransformed with the human estrogen receptor (hER) and two copies of an estrogen response element (ERE) linked to the lacZ gene, Collins et We feel that this investigation has demonstrated the utility of a combined approach, which involves computer modeling, site-directed mutagenesis, and inhibitor profile analysis using structurally related inhibitors in a molecular characterization of an inhibitor binding site. Since we have found that flavones are known to be competitive inhibitors of NAD(P)H: quinone acceptor oxidoreductase with respect to NAD(P)H (43), it is possible that these compounds also inhibit NADPH-cytochrome P450 reductase. However, we feel that this possibility is unlikely, or at least the cytochrome P450 reductase inhibition does not play a major role here because the inhibition profiles do vary for different aromatase mutants.
Phytoestrogens such as flavones, isoflavones, and flavanones are widely present in the plant kingdom with the exception of algae, fungi, and hornworts (44) . These compounds are found in all parts of the higher plants: roots, stems, leaves, flowers, pollen, fruit, seeds, wood, and bark. For example, chrysin is commonly found in flowers such as the passion flower (45) ; the genus Citrus is especially rich in flavanones such as naringenin (46) ; and genistein and biochanin A are known to be present in soybean extracts (47) . Adlercreutz et al. (48) reported that in some vegetarian women plasma genistein concentrations could be as high as 0.1 pmol/l as determined by reverse isotope dilution gas chromatography-mass spectrometry. Adlercreutz et al. (49) have also estimated that the plasma level of genistein in people on a high soy-containing diet is 1-4 pmol/l. Barnes (50) body water (56 liters), the equilibrium plasma concentration would be 3.3 pmol/l. While there has not been an extensive examination of the concentrations ofvarious phytoestrogens in our body fluids, it is estimated that the overall concentration of all flavones and isoflavones in circulation is in the micromolar range. In our study, some of the compounds are found to inhibit aromatase with JK values in the micromolar range.
The present study is an in vitro study. The effects could be different in vivo due to metabolic conversion processes. Cell culture and animal studies including these chemicals have been initiated in our laboratory. While the in vivo studies are critical for a better understanding of the action of phytoestrogens on estrogen biosynthesis, the present study provides a molecular basis regarding the binding nature and structural requirements of phytochemicals to inhibit aromatase.
Since the Women's Health Initiative is carrying out a study to test the hypothesis that a diet high in fruits and vegetables will lower breast cancer incidence in postmenopausal women, we anticipate that our study of phytoestrogens will generate information regarding which phytoestrogens are able to control estrogen biosynthesis. This will help to determine which fruits and vegetables, those containing proper phytoestrogens, should be included in a diet for postmenopausal women.
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